AI Article Synopsis
- Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different forms of the same disease, with similar treatment approaches.
- Prognostic factors such as undetectable minimal residual disease after treatment can significantly predict better survival outcomes for patients.
- Treatment decisions depend on disease characteristics, genetic mutations, age, overall health, and the side effects of the treatments, as detailed in the NCCN Guidelines.
Article Abstract
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic implications have been identified. Undetectable minimal residual disease at the end of treatment with chemoimmunotherapy or venetoclax-based combination regimens is an independent predictor of improved survival among patients with previously untreated or relapsed/refractory CLL/SLL. The selection of treatment is based on the disease stage, presence or absence of del(17p) or TP53 mutation, immunoglobulin heavy chain variable region mutation status, patient age, performance status, comorbid conditions, and the agent's toxicity profile. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CLL/SLL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.6004/jnccn.2024.0018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!